


Voriconazole camphorsulfonate

| | |
|--------------------|---|
| Cat. No.: | HY-76200B |
| CAS No.: | 137234-71-0 |
| Molecular Formula: | C ₂₆ H ₃₀ F ₃ N ₅ O ₅ S |
| Molecular Weight: | 581.61 |
| Target: | Fungal; Bacterial |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Voriconazole (UK-109496) camphorsulfonate is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole camphorsulfonate exerts its antifungal activity by inhibition of 14- α -lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes ^{[1][2]} . |
| In Vitro | Voriconazole camphorsulfonate has great activity against <i>S. apiospermum</i> and <i>C. neoformans</i> with the MICs of 0.5 μ g/mL and 0.125–0.25 μ g/mL, respectively ^[1] . Voriconazole camphorsulfonate inhibits the cytochrome P450 (CYP)-dependent enzyme 14- α -sterol demethylase, thereby disrupting the cell membrane and halting fungal growth ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Voriconazole (5–20 mg/kg; p.o. for 21 days) camphorsulfonate prolongs survival in a dose-dependent fashion. Voriconazole (40 mg/kg/day) camphorsulfonate decreases the fungal burden in the lungs ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Animal Model: | Male specific-pathogen-free BALB/cByJ mice ^[3] |
| Dosage: | 1, 5, 20 mg/kg/day |
| Administration: | P.o. once daily for 21 days |
| Result: | Improved survival in a dose-response fashion, with median survival times (MSTs) of 21, 28, and 35 days with doses of 1, 5, and 20 mg/kg, respectively. |

CUSTOMER VALIDATION

- Transl Res. 2022 Apr 20;S1931-5244(22)00073-1.
- Front Cell Infect Microbiol. 2020 Jun 26;10:320.
- Infect Drug Resist. 2022: 7459-7473.
- Med Mycol. 2018 Jun 1;56(4):452-457.

-
- Laryngoscope Investig Otolaryngol. 28 October 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Nickie D Greer. Voriconazole: the newest triazole antifungal agent.Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8.
- [2]. Lesley J Scott, et al. Voriconazole : a review of its use in the management of invasive fungal infections.Drugs. 2007;67(2):269-98.
- [3]. A M Sugar,et al. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.Antimicrob Agents Chemother. 2001 Feb;45(2):601-4.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA